Hormone Therapy

Nonadherence to Noncancer Medication Schedules Predicts Adherence to Adjuvant Hormone Therapy for Breast Cancer

By

Patients who do not adhere to their medication schedules for chronic conditions prior to a breast cancer diagnosis were twice as likely to skip oral adjuvant hormonal therapy.

Radiotherapy Plus Hormone Therapy Improves Long-term Survival for Patients With Prostate Cancer

By

Radiotherapy in combination with anti-androgen hormone therapy halves the risk of death from prostate cancer 15 years after diagnosis compared with hormone therapy alone.

Increase in Genetic Risk of Breast Cancer Triggered by Alcohol Consumption

Increase in Genetic Risk of Breast Cancer Triggered by Alcohol Consumption

By

Researchers identified a cancer-causing gene triggered by alcohol use, providing a link between alcohol and breast cancer in cell-based research.

Risks of Adverse Effects Lower With Surgical Castration Vs. Chemical Castration for Metastatic Prostate Cancer

By

Surgical castration via orchiectomy for metastatic prostate cancer is associated with lower risks for adverse effects compared with medical castration via GnRHa therapy.

Combination Therapy Proven Beneficial for Asian Women With Endocrine-resistant Breast Cancer

By

Data collected from Japanese and Korean participants in the global PALOMA3 trial provide evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with advanced HR+/HER2- breast cancer.

Docetaxel With Long-term Hormone Therapy Improves Survival in Prostate Cancer

By

Docetaxel should be added at initiation of standard of care treatment in men with prostate cancer; however, no evidence of survival improvement was seen with zoledronic acid therefore it is not recommended as part of standard of care for this patient population.

Combination Estrogen/Continuous Progestin Reduces Postmenopausal Risk of Endometrial Cancer

Combination Estrogen/Continuous Progestin Reduces Postmenopausal Risk of Endometrial Cancer

By

Adding continuous progestin to estrogen lowers the risk of endometrial cancer in postmenopausal women, according to a new study.

Medical Records Reveal Alzheimer Diagnoses Higher Among Patients Receiving ADT for Prostate Cancer

By

In a study that demonstrates the emerging technique of extracting biomedical data from ordinary patient medical records, a nearly 2-fold increase was seen in the rate of Alzheimer disease diagnoses among men with prostate cancer who received ADT.

Gene Expression Test Can Lead to More Effective Treatment Decisions In Patients With Invasive Lobular Carcinoma (ILC) Breast Cancer

By

Most patients with invasive lobular carcinoma (ILC) breast cancer could be treated with hormones alone and not with chemotherapy.

Antiandrogen Therapy (AAT) Improves Survival In Prostate Cancer Recurrence After Prostatectomy

Antiandrogen Therapy (AAT) Improves Survival In Prostate Cancer Recurrence After Prostatectomy

By

Overall survival in men with rising PSA levels after prostatectomy for prostate cancer was statistically improved by adding a 24-month course of AAT during and after salvage radiotherapy, compared with salvage radiotherapy alone.

New Approach Tackles Hormone Therapy Resistance in Breast Cancer

By

Researchers discovered a new explanation for why women with ER+ breast cancer develop resistance to hormone treatment, and a potential new approach that may overcome the problem.

Chemotherapy may be the preferred option for some patients with advanced prostate cancer

Chemotherapy may be the preferred option for some patients with advanced prostate cancer

By

In a small clinical trial, scientists found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant.

Patients older than 60 years on hormone therapy for luminal A breast cancer may not need radiation

By

Women with luminal A subtype breast cancer, especially those older than 60 years, may not need radiation treatment if they are already taking hormone therapy.

Why do some prostate cancer patients experience more hot flashes?

Why do some prostate cancer patients experience more hot flashes?

By

Researchers are examining what factors might make patients with prostate cancer more likely to experience hot flashes during and after therapy.

Combined radiation and hormone therapy improves survival in node-positive prostate cancer

Combined radiation and hormone therapy improves survival in node-positive prostate cancer

By

Men with prostate cancer that has spread to nearby lymph nodes may find the addition of radiation therapy to treatments that block the effects of testosterone beneficial.

Hormone-blocking drug prevents ovarian failure and improves fertility in breast cancer patients

By

Breast cancer patients given the hormone-blocking drug goserelin during chemotherapy experience less ovarian failure and are more likely to have successful pregnancies, according to study results.

Radiation plus hormone therapy prolongs survival for older men with prostate cancer

By

The addition of radiation treatment to hormone therapy reduced more cancer deaths among older men locally advanced prostate cancer, compared to hormone therapy alone.

Long-term testosterone therapy does not increase risk of prostate cancer

By

Current evidence seems to indicated that withholding T therapy in hypogonadal men cannot be justified.

Prostate cancer medications linked to increased heart-related deaths in some men

By

Some prostate cancer medications are linked to an increased risk of dying from heart-related causes in men with congestive heart failure or with a history of prior heart attacks.

Hormones after breast cancer: natural steroid hormones may be safe, effective

Hormones after breast cancer: natural steroid hormones may be safe, effective

A new study suggests a safe and effective role for natural steroid hormones in treating postmenopausal breast cancer, with fewer detrimental side effects and improved health profile than with standard antihormone therapies.

Anti-androgen therapy may benefit wider spectrum of patients with triple-negative breast cancer

By

Up to a third of triple-negative breast cancer tumors express the androgen receptor. Trails are underway with drugs to inhibit the androgen receptor in much the same way that tamoxifen inhibits the estrogen receptor in ER-positive breast cancers.

Does frailty influence the use of adjuvant hormone treatment in older breast cancer patients?

Does frailty influence the use of adjuvant hormone treatment in older breast cancer patients?

By

Many patients older than 65 years with localized breast cancer are eligible for adjuvant hormonal therapy, but little is known about why patients start and stop treatment.

Study Results Demonstrate A New Prostate Cancer Treatment

Study Results Demonstrate A New Prostate Cancer Treatment

A new study is suggesting a different approach to treating prostate cancer. Researchers at Comprehensive Cancer Centers of Nevada conducted a study in which 790 men with advanced stages of prostate cancer received early chemotherapy.

Enzalutamide Improves Survival in Patients with Advanced Prostate Cancer

Enzalutamide Improves Survival in Patients with Advanced Prostate Cancer

In an international randomized phase III clinical trial, the hormone therapy enzalutamide extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy.

Progesterone could be added to brain cancer therapies

Progesterone could be added to brain cancer therapies

The hormone progesterone could become part of therapy against the most aggressive form of brain cancer.

Most older patients use hormone therapy to treat their breast cancer

Most older patients use hormone therapy to treat their breast cancer

Except for frail patients, most participants in a large study complied with their oncologists' recommendations to treat their estrogen-positive breast cancer with hormone therapy.

Apoptotic Death of Prostate Cancer Cells by a GnRH-II Antagonist

Apoptotic Death of Prostate Cancer Cells by a GnRH-II Antagonist

Gonadotropin-releasing hormone-I (GnRH-I) has attracted strong attention as a hormonal therapeutic tool, particularly for androgen-dependent prostate cancer patients. Here, we investigated the effect of SN09-2 on the growth of PC3 prostate cancer cells.

New target for prostate cancer resistant to hormone therapies

By

A protein called BET bromodomain protein 4 binds to the androgen receptor downstream of where current therapies work, where it targets androgen receptor signaling. This new study suggests a way to block hormones, since prostate cancer that becomes resistant to current treatments might remain sensitive to a drug that targets BET bromodomain proteins.

Six months hormone therapy plus radiation therapy improves prostate cancer survival

By

Men with prostate cancer that is small and confined to the prostate gland but at risk of growing, do better if they are treated with radiotherapy combined with androgen deprivation therapy.

Blood-based biomarker may determine enzalutamide resistance in prostate cancers

Blood-based biomarker may determine enzalutamide resistance in prostate cancers

By

Men with metastatic, castration-resistant prostate cancer who started treatment with enzalutamide and had the molecule AR-V7 present in CTCs obtained prior to treatment had a worse response to enzalutamide.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs